Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis-Reference-Cited by-同舟云学术

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis

Published:2018-12 Issue:1 Volume:7 Page:
ISSN:2045-4015
Container-title:Israel Journal of Health Policy Research
language:en
Short-container-title:Isr J Health Policy Res

Author:

Ginsberg Gary M.^ORCID,Somekh Eli,Schlesinger Yechiel

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy

Link

http://link.springer.com/content/pdf/10.1186/s13584-018-0258-4.pdf

Reference88 articles.

1. Centers for Disease Control and Prevention. CDC Data and Statistics: Respiratory Synocitial Virus (RSV). http://www.cdc.gov/rsv/research/us-surveillance.html . Accessed 23 Sept 2018.

2. Central Bureau of Statistics. Monthly bulletin of statistics - July 2016, Jerusalem 2016. http://www.cbs.gov.il/webpub/pub/text_page_eng.html?publ=93 . Accessed 23 Sept 2018.

3. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415–20 Erratum in: Pediatrics. 2014; 134(6):1221.

4. Central Bureau of Statistics. Statistical Abstract of Israel 2015 no 66. Jerusalem 2015. http://www.cbs.gov.il/reader/shnaton/shnatone_new.htm?CYear=2015&Vol=66&CSubject=30 . Accessed 23 Sept 2018.

5. WHO Commission on MacroEconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of including productivity costs in economic analyses of vaccines for C. difficile infections and infant respiratory syncytial virus, in a UK setting;Cost Effectiveness and Resource Allocation;2024-04-30

2. Navigating Perinatal Challenges: A Comprehensive Review of Hepatitis B Viral Infection and Pregnancy Outcomes;Cureus;2024-04-25

3. Broadening criteria for palivizumab administration does not reduce admissions for respiratory syncytial virus;Vacunas (English Edition);2024-01

4. Modeling the impact of COVID‐19 nonpharmaceutical interventions on respiratory syncytial virus transmission in South Africa;Influenza and Other Respiratory Viruses;2023-12

5. La ampliación de criterios de administración de palivizumab no disminuye los ingresos por virus respiratorio sincitial;Vacunas;2023-11